Paradigm Capital Management Inc. NY Purchases 697,010 Shares of QuidelOrtho Corporation $QDEL

Paradigm Capital Management Inc. NY increased its position in QuidelOrtho Corporation (NASDAQ:QDEL) by 84.1% in the 1st quarter, HoldingsChannel reports. The fund owned 1,525,900 shares of the company’s stock after purchasing an additional 697,010 shares during the period. QuidelOrtho accounts for about 1.0% of Paradigm Capital Management Inc. NY’s holdings, making the stock its 23rd biggest position. Paradigm Capital Management Inc. NY’s holdings in QuidelOrtho were worth $25,071,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Global Retirement Partners LLC raised its stake in QuidelOrtho by 3,691.7% in the 4th quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after acquiring an additional 886 shares during the period. Camelot Portfolios LLC bought a new position in QuidelOrtho during the fourth quarter worth about $29,000. Hantz Financial Services Inc. boosted its position in QuidelOrtho by 50.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after purchasing an additional 362 shares during the period. Larson Financial Group LLC increased its stake in shares of QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock worth $39,000 after purchasing an additional 1,015 shares in the last quarter. Finally, Leonteq Securities AG increased its stake in shares of QuidelOrtho by 555.2% in the first quarter. Leonteq Securities AG now owns 3,466 shares of the company’s stock worth $57,000 after purchasing an additional 2,937 shares in the last quarter. 99.00% of the stock is currently owned by institutional investors.

QuidelOrtho Trading Down 3.2%

Shares of QDEL opened at $16.05 on Friday. The business’s 50-day moving average price is $14.87 and its 200-day moving average price is $18.72. QuidelOrtho Corporation has a twelve month low of $9.92 and a twelve month high of $35.58. The stock has a market cap of $1.09 billion, a PE ratio of -0.90 and a beta of 0.69. The company has a quick ratio of 0.80, a current ratio of 1.43 and a debt-to-equity ratio of 1.33.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). The firm had revenue of $619.80 million during the quarter, compared to the consensus estimate of $665.23 million. QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. QuidelOrtho’s revenue was down 10.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, equities analysts forecast that QuidelOrtho Corporation will post 1.87 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on QDEL shares. Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a research note on Friday, July 17th. UBS Group reaffirmed a “neutral” rating and issued a $12.00 price objective on shares of QuidelOrtho in a report on Thursday, May 7th. Jefferies Financial Group reiterated a “hold” rating on shares of QuidelOrtho in a research note on Monday, June 29th. JPMorgan Chase & Co. increased their target price on QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a research report on Wednesday, July 1st. Finally, Zacks Research raised QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Monday, June 15th. Four research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $13.62.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.